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 44 
Abstract 45 
Diagnostic methods used in the initial and post-treatment evaluation of canine 46 
lymphoma are heterogeneous and can vary within countries and institutions. 47 
Accurate reporting of clinical stage and response assessment is crucial in 48 
determining the treatment efficacy and predicting prognosis. This study 49 
comprises a systematic review of all available canine multicentric lymphoma 50 
studies published over a period of 15 years. Data concerning clinical stage 51 
evaluation and response assessment procedures were extracted and 52 
compared. Sixty-five studies met the eligibility criteria. The survey results 53 
expose variations in diagnostic criteria and treatment response assessment in 54 
canine multicentric lymphoma. Variations in staging procedures performed and 55 
recorded led to an unquantifiable heterogeneity among patients in and between 56 
studies, making it difficult to compare treatment efficacies. Awareness of this 57 
inconsistency of procedure and reporting may help in the design of future 58 
clinical trials. 59 
  60 
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Introduction 61 
 62 
Variation in diagnostic criteria and inconsistencies in staging procedures in 63 
veterinary cancer patients have important consequences for patient selection in 64 
clinical studies and will often preclude meaningful comparison of published data 65 
between studies. Standardizing staging and treatment response assessment 66 
criteria are therefore critical to the successful performance of clinical trials and 67 
to subsequent evaluations and comparisons of study outcomes.  68 
 69 
Canine lymphoma is a heterogeneous group of diseases that exhibit distinct 70 
biological behaviors according to histological subtype and extent of systemic 71 
distribution.1,2 In addition to histopathological classification, clinical stage is one 72 
of the most important prognostic factors and may therefore represent a key 73 
variable in dictating treatment with respect to drug choice. Indeed, modern 74 
methods for diagnosis and staging of human lymphoma have improved in 75 
parallel with the spectrum of therapeutic options in recent years.3 76 
Modern lymphoma classifications are based on the rationale of defining clinico-77 
pathological disease entities, enabling greater insight into the biological 78 
mechanisms that underlie specific diseases and the clinical consequences in 79 
terms of progression patterns and responses to different treatments.4,5 The 80 
ultimate goal is to develop treatment protocols that are specifically tailored to 81 
the characteristics of the individual disease entity.6 82 
Much emphasis has lately been placed on the morphological subtype of 83 
disease.1,4,7 Whereas morphological subtype is not expected to change in 84 
response to therapy, for accurate evaluation of treatment response, a complete 85 
knowledge of lymphoma extension prior to therapy makes it possible to 86 
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accurately re-stage dogs at the end of therapy and thus to define the quality of 87 
response. Standardized methods for staging are essential to make critical 88 
assessments and comparisons between different therapeutic strategies; 89 
incomplete or inconsistent staging work-up impedes comparison of study 90 
results. 91 
Currently, controversies exist regarding the extent of staging work-up that 92 
needs to be carried out at initial presentation and after completion of 93 
chemotherapy to assess treatment response. Over the years, much of this 94 
controversy arose from the assumption that an extensive staging work-up, while 95 
it might result in stage migration, did not influence prognosis or therapy.8 96 
Recent progress in the field of canine lymphoma is not limited to improvements 97 
in determining morphological subtype. Refinements have also been made in 98 
molecular diagnosis and detection of minimal residual disease (MRD). A 99 
prognostic impact of the presence of MRD as detected by thymidine kinase 100 
assay9 or PARR (PCR for Antigen Receptor Rearrangement) testing10 has been 101 
demonstrated. While progress has been made in the publication of consensus 102 
guidelines concerning the standardization of lymph node assessment by 103 
physical examination (VCOG, Veterinary Cooperative Oncology Group), in the 104 
light of such recent progress, it can now be considered very likely that these 105 
guidelines would tend to overstate complete remission rates and understate 106 
progression rates.11 107 
 108 
In order to continue the current trajectory of progress in our understanding and 109 
management of canine lymphoma, and to be able to retrospectively evaluate 110 
and compare between clinical studies, it is clear that there is a need for greater 111 
Page 5 of 40
Veterinary and Comparative Oncology
Veterinary and Comparative Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 6 
accuracy in the staging of lymphoma at first presentation and the assessment of 112 
treatment response. 113 
In this systematic review, data that report various staging methods in canine 114 
lymphoma are summarized. The main aim was to determine to what extent 115 
different approaches to evaluate treatment efficacy were comparable. In 116 
conclusion, we will make some recommendations for further studies that may 117 
help address significant unresolved clinical issues surrounding the disease. 118 
 119 
 120 
Methods 121 
 122 
Literature search and study selection processes 123 
A literature search limited to manuscripts published from January 1999 to 124 
December 2014 was performed. The search was limited to a 15 year period to 125 
ensure the studies represented contemporary diagnostic procedures and 126 
management options. 127 
A systematic MEDLINE search of articles was conducted by using the following 128 
search terms: “lymphoma” AND “dog” OR “canine” AND “treatment” OR 129 
“therapy” OR “chemotherapy” OR “immunotherapy” OR “adoptive therapy” AND 130 
“prognosis” OR “outcome” OR “assessment” OR “survival” OR “progression” 131 
OR “remission” OR “relapse” OR “disease-free”. The following were inclusion 132 
criteria for the studies to be selected: the article was published in English; the 133 
full text was available for review; the number of cases was more than 5; and 134 
finally the study was published in a peer-reviewed journal. Eligible studies for 135 
inclusion in the final data analysis were those evaluating the efficacy of first-line 136 
protocols for canine multicentric lymphoma. Exclusion criteria were studies 137 
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 7 
describing dogs with extranodal lymphoma, dogs undergoing rescue treatment, 138 
or dogs for which treatment efficacy was not recorded. 139 
After the initial search, article titles and abstracts were first evaluated for 140 
relevance and potential exclusion, then the studies included for manuscript 141 
review were subjected to full article review. The resulting list was therefore 142 
screened for non-research articles, duplicates, case reports and irrelevant 143 
references. 144 
Two authors were assigned to a time-period as follows: 1999-2001 MD and 145 
OAG, 2002-2004 IG and JH, 2005-2007 TH and GL, 2008-2011 LM and EM, 146 
2012-2014 DS and GAP. Selected papers were independently reviewed on the 147 
basis of the selected criteria by the two authors for each assigned time period 148 
and a consensus on the requested information was reached.  149 
 150 
Data extraction 151 
Studies were selected based on completeness of data and inclusion criteria 152 
only. From eligible articles, the following data were extracted: study 153 
characteristics (authors, nationality, publishing year, journal), study design 154 
(prospective versus retrospective, randomized versus non-randomized, 155 
controlled versus non-controlled), recruitment period, recruiting practices/ 156 
institutions, disease (all histotypes versus B-cell lymphoma versus T-cell 157 
lymphoma versus specific histotype), number of enrolled dogs, staging work-up 158 
(including complete blood count and serum biochemical profile, urinalysis, 159 
thoracic radiographs, abdominal radiographs, abdominal ultrasound, fine-needle 160 
aspirate of liver and spleen, bone marrow aspirate, flow cytometry to quantify 161 
peripheral blood and bone marrow infiltration, others), diagnosis (histological 162 
review with or without immunohistochemistry, cytological review, flow 163 
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 8 
cytometry), type of chemotherapeutic protocol (drugs used, duration), type of 164 
remission assessment (physical examination and subjective assessment of 165 
lymph node size reduction/ enlargement, with or without confirmative cytology, 166 
flow cytometry, PARR), duration of first remission, and survival time. 167 
 168 
Any uncertainty about the inclusion of data from any article was resolved with a 169 
consensus meeting. No attempt was made to contact authors for additional 170 
information. 171 
 172 
Descriptive analysis 173 
Descriptive analysis was performed to present the proportion of studies with 174 
each characteristic. Given the small sample size and heterogeneous study 175 
methodologies, no statistical comparisons were performed. 176 
 177 
Agreement by the Editors and Participants of the European Canine 178 
Lymphoma Network 179 
The European Canine Lymphoma Network (ECLN) is a network created in 2009 180 
with the aim of establishing cooperation among different institutions working on 181 
canine lymphoma across the fields of diagnosis and therapy.12 The definition of 182 
common guidelines and approaches is one of the main goals of ECLN. This 183 
review was submitted to the 25 Editors and Participants of Workgroup 2. The 184 
review was planned to be submitted to a peer-reviewed journal only if at least 185 
75% of the participants agreed on its content.  186 
 187 
 188 
Results 189 
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 9 
The initial search yielded over 508 references, many of which were not 190 
specifically relevant to our topic. After the exclusion of irrelevant studies, 63 191 
articles that appeared relevant to our aim and that met all study criteria were 192 
identified and fully reviewed.4,10,13-72 The main characteristics of the included 193 
studies are summarized in Table 1. 194 
 195 
Among these studies, 40 (63.5%) were from the USA, 9 (14.3%) were from 196 
Italy, 3 (4.8%) were from Germany, 3 (4.8%) were from Brazil, 2 (3.2%) were 197 
from Japan, 2 (3.2%) were from UK, 2 (3.2%) were from The Netherlands, 1 198 
(1.6%) was from France, and 1 (1.6%) was from Poland.  199 
Forty-five (71.4%) studies were conducted in single centres, 7 (11.1%) were 200 
multicentre studies and 6 (9.5%) were undertaken by two centres. The number 201 
of recruiting practices was not stated in 5 (7.9%) studies. 202 
Thirty-seven (58.7%) studies were conducted prospectively, 7 of which were 203 
randomized controlled trials comparing chemotherapy alone with chemotherapy 204 
and steroids, chemotherapy alone and chemo-immunotherapy, chemotherapy 205 
alone and chemotherapy plus total body hyperthermia, chemotherapy plus 206 
control diet and chemotherapy plus experimental diet, or two different 207 
chemotherapy protocols. Three studies were Phase 1 clinical trials. Twenty-five 208 
(39.7%) studies were retrospective and the design of 1 (1.6%) study was 209 
unclear.  210 
 211 
The median number of dogs per study was 46 (mean, 58; range, 7-456; IQR, 212 
interquantile range, 63). 213 
Forty-nine (77.8%) studies included all lymphoma histotypes; 10 (15.9%) 214 
studies focused on B-cell lymphomas (3 specifically on high-grade B-cell 215 
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lymphoma and 2 on diffuse large B-cell lymphoma, DLBCL); 4 (63.5%) focused 216 
on T-cell lymphoma (1 specifically on high-grade T-cell lymphoma) (Figure 1).  217 
Depending on the study, dogs had diagnostic assessment of disease by 218 
cytological review only (n=12; 19%), histological review only (n=17; 27%), 219 
cytology or histology (n=20; 31.7%), cytology and histology (n= 13; 20.6%), 220 
whereas the diagnostic method was not stated in 1 (1.6%) study.  221 
Immunophenotype of disease was determined either by flow cytometry or by 222 
immunohistochemistry or by PARR in 47 (74.6%) of the 63 studies examined. 223 
Immunophenotype of disease was determined in all dogs in 29 (46%) studies, in 224 
the majority to half of the cases in 5 (7.9%) studies, and only occasionally (less 225 
than 50% of cases) in 13 (20.6%) studies.  226 
 227 
The evaluation of disease extent differed significantly among studies. In 52 228 
(82.5%) studies, staging work-up was described, while in 11 (17.5%) studies the 229 
tests performed to assess disease extent were not mentioned. 230 
Considering the 52 studies in which staging was described, the most commonly 231 
suggested tests included a complete blood cell count (CBC), serum biochemical 232 
profile (83.1%), and/or urinalysis (100%), thoracic radiographs (82.7%), 233 
abdominal radiographs (28.8%), abdominal ultrasound examination with or 234 
without fine-needle aspiration of liver and spleen regardless of their sonographic 235 
appearance (59.6%), and bone marrow evaluation (73.1%). In some studies, 236 
the following tests were also performed: serology for infectious diseases (3.8%), 237 
and echocardiography and/or electrocardiography (9.6%). 238 
For the purpose of this analysis, staging procedures were grouped in the 239 
following categories: minimum work-up (including a CBC and serum 240 
biochemical profile and/or radiography or ultrasound, and/or bone marrow 241 
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evaluation; 25 [39.7%] studies) or full staging (including a CBC and serum 242 
biochemical profile, thoracic radiography, abdominal ultrasound, and bone 243 
marrow evaluation; 27 [42.8%] studies) (Figure 2). When specifically focusing 244 
on studies in which a full-staging was suggested, tests were not always 245 
performed on all dogs. 246 
 247 
The most commonly used first-line treatment protocols included vincristine, 248 
cyclophosphamide, doxorubicin, and prednisone, with or without other drugs, 249 
radiation therapy or immunotherapy (CHOP-based protocols; 45 studies, 250 
71.4%). Fourteen (22.2%) papers evaluated the efficacy of other drugs or 251 
combinations of drugs. The adopted protocol was not described in 4 (6.3%) 252 
studies.  253 
The duration of the chemotherapeutic protocols was described in 49 (77.8%) 254 
studies, and not reported in 8 (12.7%) studies. In 6 (9.5%) studies, the duration 255 
of the protocol depended on treatment response and was therefore variable. 256 
When described, the median duration of the chemotherapeutic protocol was 19 257 
weeks (range, 4 to 130 weeks; IQR, 12). 258 
 259 
Regarding treatment efficacy, if response to treatment was generically 260 
described as “regression of measurable tumours”, it was assumed that 261 
peripheral lymph nodes were at least measured. Thus, for the purpose of this 262 
review, this type of remission assessment was grouped into the category 263 
“subjective or radiological/sonographic measurement of peripheral lymph 264 
nodes”. The methods for assessing treatment response varied greatly among 265 
studies. In 41 (65.1%) studies, treatment response was based on subjective or 266 
radiological/sonographic measurement of peripheral lymph nodes; in none of 267 
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them, confirmative nodal cytology was described as mandatory. In 2 (3.2%) 268 
studies, a complete end-staging was carried out, including bloodwork, 269 
urinalysis, imaging and confirmative cytology. In 9 (14.3%) studies, minimal 270 
residual disease analysis was carried out, including flow cytometry and/or 271 
PARR. Finally, the methods were not described in 11 (17.5%) studies (Figure 272 
3). 273 
 274 
The endpoint remission duration was described in 57 (90.5%) studies; the 275 
endpoint survival was reported in slightly fewer studies (n=52; 82.5%). 276 
 277 
 278 
Discussion 279 
For each dog with suspected multicentric lymphoma, the overall goal is a timely 280 
diagnosis and administration of appropriate therapy. Needless to say, accurate 281 
staging influences management decisions and predicts prognosis for cancer 282 
patients in general. Also, clinical staging procedures allow determination of a 283 
patient’s response to therapy. Finally, clinical stage evaluations serve an 284 
important role in allowing the comparison of treatments between studies.  285 
The purpose of this work was to review the last 15 years of published literature 286 
to determine to what extent different approaches to evaluate treatment efficacy 287 
in the first-line setting were comparable. To the authors’ knowledge, there are 288 
no other published systematic reviews assessing the methods used for staging 289 
canine lymphoma at diagnosis and post treatment. 290 
 291 
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This systematic review identified a total of 63 articles that satisfied the search 292 
criteria. The total number of dogs in the current systematic review is relatively 293 
large, with a median 46 dogs per study. 294 
Based on the results of the current review, certain points of controversy were 295 
found.  296 
 297 
First, there was significant variability across studies concerning histotypes. The 298 
greatest majority of studies have been severely hampered by the admixture of a 299 
variety of lymphoma subtypes in the analysis of outcome, making it difficult to 300 
assess the clinical efficacy of any given treatment. Indeed, it has been well 301 
documented that canine lymphomas encompass a group of types of tumors, 302 
with different biologic behaviors, patterns of chemosensitivity and treatment 303 
responses.1,2 Thus, clinical trial results need to be interpreted in the context of 304 
the distribution of histologic subtypes treated. This, in turn, complicates the 305 
assessment of chemotherapy efficacy, making it impossible, in studies 306 
describing mixed lymphoma subtypes, to determine whether high or low 307 
response rates are due to the specific treatment or to the specific population 308 
under study. Only 2 out of the 63 studies evaluated a single lymphoma subtype. 309 
 310 
Second, there were striking differences in the criteria for the diagnosis and the 311 
extent of the staging procedures. These differences inevitably have an 312 
unquantifiable influence on the patients’ final outcome, and preclude meaningful 313 
comparisons between studies. Briefly, in 17.5% of the studies the staging work-314 
up was not described. Furthermore, almost half of the studies relied on a 315 
minimum work-up. Unfortunately, to date no single diagnostic algorithm 316 
sufficiently addresses the complexity and variation in disease patterns of canine 317 
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lymphoma. Furthermore, local expertise and financial resources can also 318 
influence the approach taken. Doubtless, the different opinions concerning the 319 
minimum criteria for the diagnosis of canine lymphoma do result in differences 320 
in patient selection for different chemotherapeutic protocols and therefore do 321 
bias treatment outcome.  322 
 323 
Third, the comparability of efficacy between studies was also hampered by 324 
differences in response assessment criteria employed.  325 
The importance of response assessment criteria is well described in the 326 
literature: recently, the VCOG developed a consensus document, dictating 327 
guidelines to standardize definition of normal lymph node size, when and how 328 
responses should be assessed, and definitions for response categories and 329 
endpoints.8 However, cytological and molecular diagnostic techniques allow one 330 
to state that the VCOG guidelines would tend to overstate complete remission 331 
rates and understate progression rates.8 Indeed, most of the limitations of this 332 
document reside in the inter- and intra-observer variability of physical 333 
examination, rendering the guidelines not suited for end-staging; furthermore, 334 
they do not allow assessment of MRD. A recent study has indeed shown 335 
presence of MRD by PARR despite clinical remission in 9 of 12 (75%) dogs with 336 
diffuse large B-cell lymphoma.9 As a matter of fact, despite the ease and 337 
practicality of lymph node measurement, the VCOG guidelines have not been 338 
validated in clinical and therapeutic studies. 339 
According to the results obtained here, a good proportion of studies (17.5%) did 340 
not describe the methods used for evaluating treatment response at all. The 341 
majority of studies relied on subjective or radiological measurement of 342 
peripheral lymph nodes, whereas few studies defined treatment response 343 
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based on MRD evaluation. Although the induction of clinical remission is 344 
associated with clinical benefit, RECIST criteria are restricted to measuring 345 
tumor size, being insensitive to changes in tumor load in other matrices (such 346 
as peripheral blood, bone marrow and abdominal organs), and may therefore 347 
overestimate the anti-tumor treatment effect. 348 
 349 
In this study it was shown that the absence of accurate diagnostic work-up 350 
during the initial and the end-staging may be one of the confounding factors 351 
leading to controversial results and different rates of success of antitumoral 352 
treatment in the different studies. Clearly, standardization of staging techniques, 353 
both initially and after treatment, is needed to decrease, if not eliminate, 354 
variability due to selection bias. Until the validity and reliability of measurement 355 
tools are ensured, it cannot be accurately determined which of the published 356 
treatment protocols will benefit lymphoma dogs. Awareness of these effects for 357 
patient selection and for treatment outcome may help in the design of future 358 
clinical trials. These trials will require international collaboration and should 359 
ideally be designed following multidisciplinary clinical input and include dogs 360 
classified according to histological guidelines to ensure homogeneous 361 
enrolment. 362 
 363 
The participants in the Clinical Working Group of ECLN make the following 364 
concluding observations and recommendations. 365 
While the shortcomings of retrospective studies are familiar to all, such clinical 366 
studies describing historical actions to real patients will always be of value to 367 
our understanding of treatment and disease. 368 
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When clinical information concerning canine nodal lymphoma is gained 369 
prospectively, thought must be given to the utility of that information for the 370 
scientific community at large. 371 
For all dogs enrolled in prospective studies, optimal diagnosis, clinical stage 372 
evaluation and response evaluation criteria should comprise as a minimum: 373 
 Diagnosis: WHO classification of lymphoma type and/or flow cytometry 374 
and cytomorphological analysis to define B/T immunophenotype and 375 
morphological subtype within the limits of what is possible using those 376 
diagnostic modalities. For the histopathological diagnosis of lymphoma, lymph 377 
node excision biopsies (lymphadenectomy) rather than core biopsies are 378 
regarded as standard of care.  379 
  Clinical Stage: Complete blood count and smear evaluation; thoracic 380 
and abdominal imaging (x-ray, ultrasound, CT/MRI as appropriate); cytology of 381 
splenic and hepatic aspirates, and bone marrow evaluation prior to initiation of 382 
therapy. 383 
 Response Evaluation: Two to four weeks following administration of final 384 
chemotherapy treatment for discontinuous protocols or four to six months after 385 
initiation of therapy for continuous protocols: complete blood count and smear 386 
evaluation; thoracic and abdominal imaging (x-ray, ultrasound, CT/MRI as 387 
appropriate); cytology of splenic and hepatic aspirates, bone marrow evaluation, 388 
and MRD monitoring. 389 
 390 
It is recognized that these observations and recommendations are pertinent in 391 
the present; future discoveries and trends should lead to their modification. By 392 
achieving conformity as suggested, such progress, it is hoped, will be made 393 
faster.  394 
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Captions to figures 674 
Figure 1. Pie chart showing the distribution of disease types in dogs 675 
enrolled in the 63 studies. (DLBCL: diffuse large B-cell lymphoma). 676 
 677 
Figure 2. Pie chart showing the staging methods according to the 63 678 
studies. 679 
 680 
Figure 3. Pie chart showing the methods used to assess treatment 681 
response according to the 63 studies. (LN: lymph node). 682 
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Table 1. Characteristics of included studies (chronologic order). 
 
Author (n) Study 
type 
Disease Staging methods Diagnosis methods Remission assessment 
B+U IM BM Other* C H PH LN meas C B+IM MRD 
Piek et al 1999 
(117) 
R All 
histotypes 
NR x (or) 
x 
no x no no no 
Larue et al 1999 
(42) 
P All 
histotypes 
NR no x no x no no no 
Phillips et al 
2000 (41) 
P All 
histotypes 
x x x no no x x x no no no 
Ogilvie et al 2000 
(32) 
P All 
histotypes 
x x x no no x no x no no no 
Chun et al 2000 
(49) 
P All 
histotypes 
x x x no no x OCC NR 
Boyce et al 2000 
(75) 
NR All 
histotypes 
x x OCC no x (or) 
x 
no x no no no 
Moore et al 2001 
(82) 
R All 
histotypes 
x OCC OCC no x (or) 
x 
no x no no no 
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Dobson et al 
2001 (49) 
P All 
histotypes 
x x OCC no no x x x no no no 
Garrett et al 2002 
(53) 
P All 
histotypes 
x x x no x OCC no NR 
Jagielski et al 
2002 (43) 
R All 
histotypes 
x x x no no x no x no no no 
Mutsaers et al 
2002 (33) 
P All 
histotypes 
x x x no no x no x no x (IM 
only) 
no 
Morrison-
Collister et al 
2003 (94) 
R All 
histotypes 
X x x no no x MOST x no x no 
Moore et al 2003 
(10) 
P All 
histotypes 
X x x no no x MOST x no no no 
Ponce et al 2004 
(57) 
R All 
histotypes 
x x x no x x x x no no no 
Ricci Lucas et al 
2004 (7) 
P All 
histotypes 
x x x no x x no x no no no 
Williams et al P All x x OCC x x (or) x x no x no 
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2004 (52) histotypes x 
Gustafson et al 
2004 (8) 
P All 
histotypes 
x x x no x x x x no no no 
MacDonald et al 
2005 (115) 
R All 
histotypes 
x x x no no x x NR 
Simon et al 2006 
(77) 
P All 
histotypes 
x x OCC x x (or) 
x 
MOST x no no no 
Turner et al 2006 
(21) 
P All 
histotypes 
x x x no no x no x no no no 
Siedlecki et al 
2006 (39) 
R All 
histotypes 
x x OCC no x (or) 
x 
OCC x no no no 
Turek et al 2007 
(52) 
P B-cell x x x no no x x x no no no 
Hosoya et al 
2007 (101) 
R All 
histotypes 
x x OCC no x (or) 
x 
OCC x no no no 
Kaiser et al 2007 
(96) 
R All 
histotypes 
x MOST OCC no x (or) 
x 
no x no no no 
Gavazza et al R All x no x x x no OCC NR 
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2008 (114) histotypes 
Marconato et al 
2008 (17) 
P All 
histotypes 
x x x x x no x x x x x 
Merlo et al 2008 
(20) 
P All 
histotypes 
x x no no x no no x no no no 
Rebhun et al 
2008 (31) 
R All 
histotypes 
x x x no no x x x no x no 
Simon et al 2008 
(106) 
P All 
histotypes 
x x OCC x x x OCC NR 
Gavazza et al 
2009 (114) 
R All 
histotypes 
x no x x x no OCC x no no no 
Miller et al 2009 
(84) 
R All 
histotypes 
NR x (or) 
x 
OCC NR 
Brodsky et al 
2009 (50) 
R T-cell x x OCC no x (or) 
x 
x x no no no 
Daters et al 2010 
(65) 
P All 
histotypes 
x x x no x x no x no no no 
Lori et al 2010 P All x OCC OCC no x (or) OCC x no no no 
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(32) histotypes x 
Marconato et al 
2010 (50) 
P All 
histotypes 
x x x x x no x x x x no 
Rassnick et al 
2010 (66) 
P All 
histotypes 
x x x no no x x x no x no 
Sorenmo et al 
2010 (119) 
R All 
histotypes 
x x x x x no OCC x OC
C 
NR no 
Yamazaki et al 
2010 (17) 
P All 
histotypes 
NR x no x x no no x 
Zenker et al 2010 
(17) 
P All 
histotypes 
x x OCC no x OCC no x no no no 
Sato et al 2011 
(29) 
P B-cell high 
grade 
x x no no x no x x no no no 
Marconato et al 
2011 (127) 
R All 
histotypes 
x x x x x no x x no no no 
Perry et al 2011 
(26) 
R All 
histotypes 
x no OCC x no x MOST NR 
Flory et al 2011 R All x OCC OCC no x (or) OCC NR 
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(95) histotypes x 
Rebhun et al 
2011 (24) 
R T-cell 
(intermediate 
or high 
grade) 
x x x no x (or) 
x 
x x no no no 
Sorenmo et al 
2011 (83) 
P B-cell x x x no x x x x x x no 
O’Connor et al 
2012 (8) 
P B-cell NR x x x NR 
Silver et al 2012 
(19) 
P All 
histotypes 
x x no no NR x no no no 
Willcox et al 
2012 (19) 
P B-cell NR x (or) 
x 
x no no no x 
Vail et al 2012 
(19) 
P All 
histotypes 
x OCC OCC no no x MOST x no no no 
Gentilini et al 
2013 (8) 
R B-cell  NR x no x x no no x 
Sato et al 2013 P B-cell high x x no no x no x x no no x 
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(36) grade 
Valli et al 2013 
(456) 
R All 
histotypes 
NR no x x NR 
Marconato et al 
2013 (46) 
P B-cell high 
grade 
x x x x x OCC x x x x x 
Elliott et al 2013 
(97) 
R All 
histotypes 
x MOST OCC OCC x (or) 
x 
OCC x no no no 
Burton et al 2013 
(31) 
R All 
histotypes 
NR x (or) 
x 
OCC x no no no 
Zandvliet et al 
2013 (81) 
P All 
histotypes 
x OCC x OCC x no x x no no no 
Warry et al 2014 
(14) 
P T-cell high 
grade 
NR x (or) 
x 
x no no no x 
Avery et al 2014 
(67) 
R T-cell OCC OCC OCC no x (or) 
x 
x NR 
Marconato et al 
2014 (19) 
P DLBCL x x x no x x x x x no x 
Aresu et al 2014 P DLBCL x x x no x x x x x x x 
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(14) 
Mutz et al 
2015** (77) 
R All 
histotypes 
x x OCC no x (or) 
x 
OCC x no x no 
Lucas et al 
2015** (15) 
P All 
histotypes 
x x x no x x x x no no no 
Childress et al 
2015** (15) 
P All 
histotypes 
NR x (or) 
x 
no x no no no 
 
n: number of dogs, P: prospective, R: retrospective, B+U: blood and urinalysis, IM: imaging (thoracic radiography and/or abdominal radiography and/or 
abdominal ultrasound), BM: bone marrow evaluation, C: cytology, H: histology, PH: phenotype assessment, LN meas: subjective or radiological measurement 
of peripheral lymph nodes, MRD: minimal residual disease 
NR: not reported, OCC: occasionally (<50% of cases), MOST: most cases (>50%) 
* Other: infectious disease serology or cardiac evaluation or fine-needle aspiration of liver and spleen regardless of their sonographic appearance 
** The papers published in 2015 were available for early view already when this review was started and were therefore included in the analysis. 
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Figure 1. Pie chart showing the distribution of disease types in dogs enrolled in the 63 studies. (DLBCL: 
diffuse large B-cell lymphoma).  
167x149mm (300 x 300 DPI)  
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Figure 2. Pie chart showing the staging methods according to the 63 studies.  
167x149mm (300 x 300 DPI)  
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Figure 3. Pie chart showing the methods used to assess treatment response according to the 63 studies. 
(LN: lymph node).  
167x149mm (300 x 300 DPI)  
 
 
Page 40 of 40
Veterinary and Comparative Oncology
Veterinary and Comparative Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
